# Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

> **NCT00485875** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 62 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine Hydrochloride

## Key facts

- **NCT ID:** NCT00485875
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2005-01
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2007-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485875, "Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00485875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*